Incretin concepts
- PMID: 20103551
- PMCID: PMC2809302
- DOI: 10.2337/dc10-zb02
Incretin concepts
Similar articles
-
[Incretin related agents for treatment of diabetes mellitus].Nihon Naika Gakkai Zasshi. 2009 Apr 10;98(4):809-16. doi: 10.2169/naika.98.809. Nihon Naika Gakkai Zasshi. 2009. PMID: 19472544 Review. Japanese. No abstract available.
-
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.Expert Opin Investig Drugs. 2006 Aug;15(8):887-95. doi: 10.1517/13543784.15.8.887. Expert Opin Investig Drugs. 2006. PMID: 16859392 Review.
-
Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.Curr Diabetes Rev. 2008 May;4(2):101-9. doi: 10.2174/157339908784220705. Curr Diabetes Rev. 2008. PMID: 18473757 Review.
-
Incretin effects on β-cell function, replication, and mass: the human perspective.Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S258-63. doi: 10.2337/dc11-s230. Diabetes Care. 2011. PMID: 21525465 Free PMC article. No abstract available.
-
Combination pharmacotherapy with incretins: what works best and when?Curr Diab Rep. 2008 Oct;8(5):361-7. doi: 10.1007/s11892-008-0063-5. Curr Diab Rep. 2008. PMID: 18778584
Cited by
-
Benefits of healthy adipose tissue in the treatment of diabetes.World J Diabetes. 2014 Aug 15;5(4):420-30. doi: 10.4239/wjd.v5.i4.420. World J Diabetes. 2014. PMID: 25126390 Free PMC article. Review.
-
Exenatide stimulates solute-free water clearance by the rat kidney in hyperhydration.Dokl Biol Sci. 2011 Mar-Apr;437:85-7. doi: 10.1134/S0012496611020128. Epub 2011 May 12. Dokl Biol Sci. 2011. PMID: 21562952 No abstract available.
-
Adipose tissue, hormones, and treatment of type 1 diabetes.Curr Diab Rep. 2012 Oct;12(5):542-50. doi: 10.1007/s11892-012-0300-9. Curr Diab Rep. 2012. PMID: 22814676 Review.
References
-
- Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554– 3563 - PMC - PubMed
-
- Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104: 342– 345 - PubMed
-
- Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340– 2350 - PubMed
-
- Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994; 37: 1163– 1166 - PubMed
-
- González N, Acitores A, Sancho V, Valverde I, Villanueva-Peñacarrillo ML. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 2005; 126: 203– 211 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical